Table 5.
Treatment response to anti-IL1 drugs in PASS, PAPASH, and PAC syndromes.
| ID article (IDPatient)/ Cycles |
Syndrome | DRUG/ DOSE-duration |
Previous treatment | Concomitant treatment |
Clinical efficacy | Efficacy 6-12 weeks/ 12-24 weeks/ >24 weeks/ |
Adverse events /recurrence |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SH | Acne | PG | PA | UC | AS | ||||||||||
| 15 (2)/1 | PASS | Anakinra 100mg/day 4 weeks |
Etanercept | NA | Yes (p) | Yes (p) | Yes | – | – | Yes (p) | Yes NA NA |
NA Yes |
|||
| 24 (3)/1 | PASS | Anakinra 100mg/day NA |
Ustekinumab, tocilizumab | NA | NA | – | NA | – | – | NA | No NA NA |
NA NA |
|||
| 28 (4)/1 | PASS | Anakinra 100-200mg/day 8 months |
Prednisone | Corticosteroids | No | Yes | Yes | – | – | Yes | Yes Yes No |
NA NA |
|||
| 7 (1)/1 | PAPASH | Anakinra 100mg/day NA |
Azithromycin, dapsone, methylprednisolone, topical tacrolimus, | NA | Yes (p) | NA | NA | NA | – | – | Partial | Partial | |||
| 9 (7)/1 | PAC | Anakinra 100mg/day 24 months |
Prednisolone, topical tacrolimus, infliximab, Secukinumab, prednisone and isotretinoin | Corticosteroids, Isotretinoin | – | NA | NA | – | NA | – | Partial | Total | |||
PA, pyogenic arthritis; A, acne; PG, pyoderma gangrenosusm; SH, supurative hidradenitis; SA, ankylosing spondylitis; PsA, psoriatic arthritis; UC, ulcerative Colitis; NA, not available; -, not applicable, HDIVIG, high-dose intravenous immunoglobin; c, complete (dark green colour); p, partial (green light colour); No, not response (red light colour). Partial (p) and Complete (c ). Response to treatment are terms defined by the original studies.